Item 7.01 Regulation FD Disclosure. On March 4, Marc D. Beer, the Chief Executive Officer of Aegerion Pharmaceuticals, Inc. (the "Company"), entered into pre-arranged, non-discretionary stock trading plans with a broker to facilitate the purchase up to $1,600,000 of the Company's common stock. Mr. Beer's trading plans were adopted in accordance with Rule 10b5-1 ("Rule 10b5-1") under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Company's policies governing stock transactions by directors, executive officers and other employees. Rule 10b5-1 allows corporate insiders to establish prearranged stock trading plans when they are not in possession of material non-public information.
The Rule 10b5-1 share purchase period will commence as soon as April 3, 2011, the first date the broker is eligible to begin trading pursuant to the terms of the plans, and will continue until March 15, 2012, unless terminated earlier in accordance with the terms of the plans. Purchases will be effected by a broker and will be based upon the guidelines and parameters of the Rule 10b5-1 plans. The aggregate amount of shares purchased pursuant to the plans will not exceed $1,600,000. There is no guarantee as to the exact number of shares that will be purchased under the share purchase programs, and Mr. Beer may discontinue purchases at any time.